Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 11/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.46 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3554495 | 0.90 | ADORA1 (0.56) | ADORA1ADORA2ASQORADORA2BALDH1A1 | |
| SCHEMBL3550969 | 0.90 | ADORA1 (0.49) | ADORA1ADORA2ASQORADORA2BALDH1A1 | |
| SCHEMBL3553018 | 0.87 | ADORA1 (0.52) | ADORA1ADORA2ASQORADORA2BALDH1A1 | |
| SCHEMBL3552614 | 0.87 | ADORA1 (0.52) | ADORA1ADORA2AADORA2BALDH1A1MAPT | |
| SCHEMBL3552143 | 0.87 | ADORA1 (0.46) | ADORA1ADORA2ASQORADORA2BALDH1A1 | |
| SCHEMBL3544664 | 0.85 | ADORA1 (0.47) | ADORA1ADORA2ASQORADORA2BALDH1A1 | |
| SCHEMBL3546792 | 0.85 | SQOR (0.55) | ADORA1ADORA2ASQORALDH1A1MAPT | |
| SCHEMBL3548712 | 0.83 | ADORA1 (0.55) | ADORA1ADORA2ASQORADORA2BALDH1A1 | |
| SCHEMBL13036577 | 0.82 | ADORA1 (0.56) | ADORA1ADORA2AADORA2BALDH1A1MAPT | |
| SCHEMBL3539872 | 0.82 | ADORA1 (0.69) | ADORA1ADORA2ASQORADORA2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855219-B2 | Substituted 2-oxy-3,5-dicyano-4aryl-6-aminopyridines and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-21 | — | — | US | disclosed |
| US-7855219-B2 | Substituted 2-oxy-3,5-dicyano-4aryl-6-aminopyridines and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-21 | — | — | US | disclosed |
| US-7855219-B2 | Substituted 2-oxy-3,5-dicyano-4aryl-6-aminopyridines and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-21 | — | — | US | disclosed |
| EP-1368320-B1 | SUBSTITUTED 2-OXY-3,5-DICYANO-4-ARYL-6-AMINOPYRIDINES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2006-08-16 | — | — | EP | disclosed |
| US-20050261502-A1 | Substituted 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261502-A1 | Substituted 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines and use thereof | ADORA2A, ADORA3, ADORA1 | ADORA1 3/4885ADORA2A 1/4885SQOR 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.